Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

Sponsor
University Hospital, Caen
Study ID
NCT04774406
Status
Completed

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious (or not) adverse events such as hypertension whose data are scarce. The objective was to investigate reports of hypertension related to PARPi, including olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, and fluzoparib using the World Health Organization's (WHO) pharmacovigilance database: VigiBase.

Key Dates

Start date
Feb 24, 2021
Status verified
May 2023
Primary completion
May 9, 2021
Completion
Sep 1, 2022

Study Design

Enrollment
2,336 participants (actual)

Arms

  • Arm: parp inhibitors
    All patients treated at least with 1 PARPi

Primary Outcome Measure

hypertension reports related to PARPi. [ Time Frame: From inception to 16 Feb, 2023 ]

Related Studies